<DOC>
	<DOCNO>NCT00001087</DOCNO>
	<brief_summary>Steps I II : The purpose study follow : To look many patient achieve undetectable HIV blood level Week 16 . To look absolute change HIV blood level begin study Week 16 . To look safety tolerability nelfinavir ( NFV ) efavirenz ( EFV ) use combination separately regimens contain reverse transcriptase inhibitor ( RTIs ) . For 2 extension study ( Weeks 49 144 ) : To look proportion patient whose long-term viral load remain undetectable Week 96 . To look time begin study treatment failure , patient evaluate Week 144 . Step III : To look proportion patient whose HIV blood level undetectable 16 week start salvage study treatment . To assess safety , toxicity , tolerance salvage study drug treatment . ( This study change add new objective . ) Achieving viral suppression widely endorse primary goal HIV therapy . However , establish guideline devise combination different class drug enhance potential achieve viral suppression , reduce risk toxicity , preserve therapeutic option future use . This study include 2 anti-HIV drug , NFV ( protease inhibitor [ PI ] ) EFV ( nonnucleoside reverse transcriptase inhibitor [ NNRTI ] ) , use either alone combination RTI therapy purpose limit HIV replication . Patients treatment failure Week 16 choose 1 follow 3 alternative salvage therapy : 2-drug PI regimen ( saquinavir ritonavir ) plus adefovir dipivoxil L-carnitine ; EFV NFV ( already give ) plus 2 new approve anti-HIV drug outside study ; best available treatment outside study . The new RTI , adefovir dipivoxil , add 2-drug PI regimen achieve suppression viral replication thereby delay disease progression . ( This rationale reflect change treatment give patient treatment failure Week 16 . )</brief_summary>
	<brief_title>The Effectiveness Nelfinavir Efavirenz , Used Alone Together , Combined With Other Anti-HIV Drugs Patients Who Have Taken Anti-HIV Drugs</brief_title>
	<detailed_description>Achieving viral suppression widely endorse primary goal HIV therapy , yet establish guideline provide framework devise combination different class drug enhance potential achieve viral suppression reduce risk toxicity also preserve therapeutic option future use . This study include 2 antiretroviral compound , NFV ( protease inhibitor [ PI ] ) EFV ( nonnucleoside reverse transcriptase inhibitor [ NNRTI ] ) , use either alone combination reverse transcriptase inhibitor ( RTI ) therapy purpose limit HIV replication . [ AS PER AMENDMENT 3/5/98 : Patients experience treatment failure Week 16 later choose 1 follow alternative potent salvage therapy regimen : dual-PI regimen ( saquinavir/ritonavir ) plus adefovir dipivoxil L-carnitine ; EFV NFV ( already give ) plus 2 new approve antiretroviral drug outside study ; best available treatment outside study . The new reverse transcriptase inhibitor , adefovir dipivoxil , add dual-PI regimen achieve suppression viral replication thereby delay disease progression . ] Step I : Patients detectable plasma HIV RNA level assign Group A , undetectable level assign Group B ( control ) . Group A : Patients randomize 1 3 treatment arm : NFV plus EFV placebo Arm I ; NFV placebo plus EFV Arm II ; NFV plus EFV Arm III . Concurrent randomly assign therapy , patient receive open-label RTI therapy comprise 1 follow 3 combination provide 1 2 new RTIs : didanosine ( ddI ) plus stavudine ( d4T ) ; lamivudine ( 3TC ) plus d4T ; ddI plus 3TC . [ AS PER AMENDMENT 12/02/97 : Patients virologic failure Week 16 seek best available therapy outside study continue study medication 120 day . ] [ AS PER AMENDMENT 3/5/98 : Patients virologic failure Week 16 proceed Step III . ] Patients without virologic failure continue therapy Weeks 1 48 [ AS PER AMENDMENT 3/5/98 : without virologic failure Week 48 may continue therapy Weeks 49 96 ( first extension study ) ] . [ AS PER AMENDMENT 5/27/99 : After Week 96 , patient Arm I may switch Arm III seek best available antiretroviral therapy outside study . Patients Arm II III undetectable plasma HIV RNA level Week 96 may continue therapy Weeks 97 144 ( second extension study ) seek best alternative antiretroviral therapy . Patients Arm II III detectable plasma HIV RNA level without virologic failure Week 48 continue current study therapy proceed Step III . Patients confirm virologic failure Week 48 later proceed Step III seek best available alternative therapy outside study . ] Group B : Patients receive treatment assign , open-label ACTG 302/303 regimen . Patients detectable plasma HIV RNA level discontinue Group B therapy proceed Step II . Patients undetectable plasma HIV RNA level continue therapy Weeks 1 48 [ AS PER AMENDMENT 6/24/98 : undetectable level Week 48 may continue therapy Weeks 49 96 ( first extension study ) ] . [ AS PER AMENDMENT 5/27/99 : Patients undetectable level Week 96 may continue therapy Weeks 97 144 ( second extension study ) . ] Step II : Patients receive treatment Group A . [ Step III : AS PER AMENDMENT 3/5/98 : Patients choose 1 3 alternative therapy : saquinavir soft gel capsule , ritonavir , adefovir dipivoxil , L-carnitine Arm X ; EFV NFV plus 2 new approve antiretroviral drug outside study Arm Y ( prior EFV NFV ) ; best available medication outside study Arm Z . Patients Arm X Y follow salvage therapy 24 48 week . Patients detectable plasma HIV RNA level 16 week salvage therapy encourage discontinue study medication seek best alternative treatment . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Chemoprophylaxis Pneumocystis carinii pneumonia patient CD4 count 200 cells/mm3 less . Allowed : Topical oral antifungal except oral ketoconazole . Treatment , maintenance , chemoprophylaxis approve agent opportunistic infection clinically indicate . All antibiotic clinically indicate . Systemic corticosteroid use 21 day acute problem medically indicate . Note : Steroid use 21 day consider casebycase basis . Recombinant erythropoietin ( rEPO ) granulocyte colonystimulating factor ( GCSF ) medically indicate . Regularly prescribed medication antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive , megestrol acetate , testosterone , medication medically indicate . [ AS PER AMENDMENT 4/25/00 : Allowed caution : Pentamidine , allopurinol , hydroxyurea . Use medication may increase exposure ddI . ] Concurrent Treatment : Allowed : Dependency le 3 unit blood per 21day period . Alternative therapy acupuncture visualization technique . Patients must : HIV infection document licensed ELISA confirm Western blot , positive HIV culture , positive HIV antigen , positive plasma HIV RNA , second antibody test positive method ELISA . Repeat HIVantibody test require enrollment trial ( implicit patient enrol ACTG 302/303 ) . Signed , inform consent parent legal guardian patient 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Inability tolerate ddI 200400 mg/day , 3TC 300 mg/day , d4T 6080 mg/day , intolerance define recurrent toxicity require dose interruption reduction permanent discontinuation drug ( Grade 3 4 anemia ) . Grade 2 high peripheral neuropathy . Malignancy require systemic therapy . Coenrollment antiretroviral protocol ; coenrollment ACTG protocols encourage , particularly involve prophylaxis opportunistic infection . Concurrent Medication : Excluded : All antiretroviral therapy study medication . Investigational drug vaccine without specific approval Protocol Chair/Vice Chairs . Systemic cytotoxic chemotherapy . Interferon , interleukins , GMCSF , HIV1 vaccine . Rifabutin rifampin . Ketoconazole , astemizole , cisapride , midazolam , terfenadine , triazolam . Acute therapy infection medical illness . Herbal medication . Vitamins . [ 10 . AS PER AMENDMENT 3/5/98 : Ergot alkaloid drug contain derivative ergot alkaloid . ] Patients follow prior condition exclude : History acute chronic pancreatitis . Prior Medication : Excluded : PIs . NNRTIs . Acute therapy infection medical illness within 14 day prior time study entry . Chronic longterm steroid use permit unless within physiologic replacement level ; protocol chair/vice chair must contact instance . Risk Behavior : Excluded : Current ethanol abuse personal history report primary physician .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Adenine</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>efavirenz</keyword>
</DOC>